FDAnews Drug Daily Bulletin

Gilead Sciences to Promote Low-Cost HIV Medicine in Developing World

Aug. 6, 2012
Gilead Sciences said it plans to partner with Mylan, Ranbaxy Laboratories and Strides Arcolab to promote access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries.
The Wall Street Journal